BRIEF

on Darwin AG (isin : DE000A3C35W0)

Novogenia Reports Revenue Growth Amidst International Expansion

In the third quarter of 2026, Novogenia AG saw a 27% increase in quarterly revenue, amounting to EUR 17.4 million. This growth stems primarily from the recovery in pharmaceutical and medical device trading, reaching EUR 43.0 million in the first nine months. Despite the improved revenue, EBIT was reported at EUR -2.6 million due to lower-margin revenue and a reduced cost base from personnel and operating expenses.

The company’s strategic focus remains on international expansion and genetic analysis products. Key partnerships, such as those with 10X Health in the US and initiatives in the Middle East, are opening new market opportunities. The equity ratio also saw a slight increase, standing at 84.6% by the end of September.

CEO Dr. Wallerstorfer emphasizes translating this growth into stronger earnings, aligning with their expanded service range. The company remains optimistic about continued growth into the next financial year, backed by its advancements in international markets and robust product pipeline.

R. H.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Darwin AG news